By A recent presentation at The Menopause Society annual meeting in San Diego has sparked a conversation about the potential cardiac risks associated with testosterone therapy in postmenopausal women. Researchers analyzed data from over 6,000 women aged 45 and older, excluding those with prior histories of heart disease, to see how the hormone treatment impacted long term health. Their findings revealed that roughly 3.8 percent of women using testosterone experienced a first time cardiovascular event, such as a heart attack or stroke, compared to just 0.5 percent of those who did not receive the therapy.
Medical professionals note that while these figures represent a notable increase in frequency, they must be interpreted with caution. Dr. Anna Cabeca, a board certified OB GYN and menopause specialist, pointed out that the gap translates to approximately 38 events per 1,000 treated women versus five per 1,000 untreated women. While she believes this discrepancy warrants serious attention, she emphasizes that the study was observational rather than a controlled clinical trial. This means researchers observed existing patterns rather than controlling all variables, leaving open the possibility that other underlying health factors influenced the results.
Because testosterone plays a critical role in everything from cognitive function and bone density to sexual desire and mood, many women seek out the therapy to combat common menopausal symptoms. Experts argue that sexual health remains an essential component of overall well being and that patients deserve to have their struggles with libido and intimacy addressed seriously by their providers. However, they suggest that any decision to start hormone therapy should involve a comprehensive review of a patient’s blood pressure, cholesterol levels and family medical history.
Ultimately, clinicians advise that for those who are deemed appropriate candidates for testosterone therapy, the key lies in precision and vigilance. Careful dosing combined with frequent laboratory tests and symptom monitoring can help mitigate risks while maximizing benefits. For now, specialists view these findings as an important safety signal that requires deeper investigation rather than absolute proof that the hormone causes heart complications in all users.
